JP2025516407A - Ｖｖｎ００１含有眼科組成物 - Google Patents

Ｖｖｎ００１含有眼科組成物 Download PDF

Info

Publication number
JP2025516407A
JP2025516407A JP2023560923A JP2023560923A JP2025516407A JP 2025516407 A JP2025516407 A JP 2025516407A JP 2023560923 A JP2023560923 A JP 2023560923A JP 2023560923 A JP2023560923 A JP 2023560923A JP 2025516407 A JP2025516407 A JP 2025516407A
Authority
JP
Japan
Prior art keywords
acid
ophthalmic composition
sodium
group
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516407A5 (https=
Inventor
夏尓寧
韓巧
沈旺
陸陽清沁
高紅妍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivavision Biotech Ltd
Original Assignee
Vivavision Biotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivavision Biotech Ltd filed Critical Vivavision Biotech Ltd
Publication of JP2025516407A publication Critical patent/JP2025516407A/ja
Publication of JP2025516407A5 publication Critical patent/JP2025516407A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023560923A 2023-04-27 2023-05-25 Ｖｖｎ００１含有眼科組成物 Pending JP2025516407A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202310476403.2A CN118892446A (zh) 2023-04-27 2023-04-27 一种含vvn001的眼科组合物
CN202310476403.2 2023-04-27
PCT/CN2023/096273 WO2024221527A1 (zh) 2023-04-27 2023-05-25 一种含vvn001的眼科组合物

Publications (2)

Publication Number Publication Date
JP2025516407A true JP2025516407A (ja) 2025-05-30
JP2025516407A5 JP2025516407A5 (https=) 2025-10-03

Family

ID=93255459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560923A Pending JP2025516407A (ja) 2023-04-27 2023-05-25 Ｖｖｎ００１含有眼科組成物

Country Status (9)

Country Link
EP (1) EP4702974A1 (https=)
JP (1) JP2025516407A (https=)
KR (1) KR20240159657A (https=)
CN (1) CN118892446A (https=)
AU (1) AU2023361985B2 (https=)
CA (1) CA3238321A1 (https=)
IL (1) IL312531A (https=)
TW (1) TW202442220A (https=)
WO (1) WO2024221527A1 (https=)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018764A2 (en) * 1992-03-18 1993-09-30 Coopervision Pharmaceuticals, Inc. VERAPAMIL HCl FORMULATION AND OTHER OPHTHALMIC SOLUTIONS WITH BUFFER SYSTEM FOR OCULAR ADMINISTRATION
JP2001511135A (ja) * 1997-01-29 2001-08-07 ボシュ アンド ロム インコーポレイテッド グリセリンおよびプロピレングリコールを含有する眼科用組成物
WO2016072440A1 (ja) * 2014-11-07 2016-05-12 参天製薬株式会社 眼科用水性組成物
JP2020519563A (ja) * 2017-06-27 2020-07-02 ▲維▼眸生物科技上海有限公司Ｖｉｖａ Ｖｉｓｉｏｎ Ｓｈａｎｇｈａｉ Ｌｔｄ リン含有化合物及びその製造並びにそれを用いた医薬品
JP2022501437A (ja) * 2018-09-25 2022-01-06 シェンヤン シンチ ファーマシューティカル カンパニー, リミテッドShenyang Xingqi Pharmaceutical Co., Ltd. 低濃度アトロピン眼科用製剤の安定性を改善するための方法
WO2022101821A1 (en) * 2020-11-12 2022-05-19 Sifi S.P.A. Formulation based on polyhexamethylene biguanide for use in the treatment of acanthamoeba keratitis and/or fungal infections
WO2022207773A1 (en) * 2021-04-01 2022-10-06 Active Biotech Ab Laquinimod formulation for ocular use
JP2023505409A (ja) * 2019-08-18 2023-02-09 アイビュー セラピューティクス（ズーハイ）カンパニー リミテッド 持続型の眼用薬物送達システムとしてシクロスポリンミセルを含むｉｎ－ｓｉｔｕゲル

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019001171A1 (zh) * 2017-06-27 2019-01-03 维眸生物科技上海有限公司 一种含磷化合物及其制备和应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018764A2 (en) * 1992-03-18 1993-09-30 Coopervision Pharmaceuticals, Inc. VERAPAMIL HCl FORMULATION AND OTHER OPHTHALMIC SOLUTIONS WITH BUFFER SYSTEM FOR OCULAR ADMINISTRATION
JP2001511135A (ja) * 1997-01-29 2001-08-07 ボシュ アンド ロム インコーポレイテッド グリセリンおよびプロピレングリコールを含有する眼科用組成物
WO2016072440A1 (ja) * 2014-11-07 2016-05-12 参天製薬株式会社 眼科用水性組成物
JP2020519563A (ja) * 2017-06-27 2020-07-02 ▲維▼眸生物科技上海有限公司Ｖｉｖａ Ｖｉｓｉｏｎ Ｓｈａｎｇｈａｉ Ｌｔｄ リン含有化合物及びその製造並びにそれを用いた医薬品
JP2022501437A (ja) * 2018-09-25 2022-01-06 シェンヤン シンチ ファーマシューティカル カンパニー, リミテッドShenyang Xingqi Pharmaceutical Co., Ltd. 低濃度アトロピン眼科用製剤の安定性を改善するための方法
JP2023505409A (ja) * 2019-08-18 2023-02-09 アイビュー セラピューティクス（ズーハイ）カンパニー リミテッド 持続型の眼用薬物送達システムとしてシクロスポリンミセルを含むｉｎ－ｓｉｔｕゲル
WO2022101821A1 (en) * 2020-11-12 2022-05-19 Sifi S.P.A. Formulation based on polyhexamethylene biguanide for use in the treatment of acanthamoeba keratitis and/or fungal infections
WO2022207773A1 (en) * 2021-04-01 2022-10-06 Active Biotech Ab Laquinimod formulation for ocular use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INFLAMMATION, vol. 44, no. 2, JPN6025024748, 2021, pages 780 - 794, ISSN: 0005754108 *
OPTOMETRY, vol. 75, no. 3, JPN6025024749, 2004, pages 161 - 168, ISSN: 0005754110 *
THE OCULAR SURFACE, vol. 28, JPN6025024747, 2023, pages 18 - 24, ISSN: 0005754109 *

Also Published As

Publication number Publication date
TW202442220A (zh) 2024-11-01
EP4702974A1 (en) 2026-03-04
CN118892446A (zh) 2024-11-05
AU2023361985A1 (en) 2024-11-14
KR20240159657A (ko) 2024-11-05
CA3238321A1 (en) 2025-07-08
AU2023361985B2 (en) 2025-08-14
IL312531A (en) 2024-11-01
WO2024221527A1 (zh) 2024-10-31

Similar Documents

Publication Publication Date Title
US20100130550A1 (en) Ocular formulations of norketotifen
WO2020072621A1 (en) Contact lens solutions and kits
US9694003B2 (en) Formulations and methods for treating high intraocular pressure
US20200129505A1 (en) Topical Brimonidine Tartrate Ophthalmic Solution
US11701343B2 (en) Compositions and methods for treating ocular disorders
US20110178145A1 (en) Alpha-2 adrenergic agonist having long duration ofintraocular pressure-lowering effect
EP3593788B1 (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
US20110123622A1 (en) Ophthalmic formulation and method of manufacture thereof
JP2025516407A (ja) Ｖｖｎ００１含有眼科組成物
US20210369728A1 (en) Ophthalmic composition of brinzolamide and brimonidine
JP2025516407A5 (https=)
HK40113077A (zh) 一种含vvn001的眼科组合物
KR20230145458A (ko) 우르소데옥시콜산 또는 그 염을 함유하는 수성 의약 조성물
EP4230193A1 (en) Ophthalmic pharmaceutical composition
US20260060973A1 (en) Ophthalmic Composition for Treating Non-Infectious Inflammatory Diseases
WO2021210646A1 (ja) エピナスチン又はその塩を含有する水性組成物
TW202442233A (zh) 一種用於治療非感染性炎症疾病的眼科組合物
HK40113256A (zh) 一种用於治疗非感染性炎症疾病的眼科组合物
WO2024034592A1 (ja) Ｕｄｃａまたはその塩を含有する水性医薬組成物
HK40018890B (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
HK40018890A (en) Ophthalmic compositions containing a nitric oxide releasing prostamide
HK1228759A1 (en) Composition effective against viral conjunctivitis

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260311